Nephros (NASDAQ:NEPH) Now Covered by Analysts at Northland Securities

Northland Securities began coverage on shares of Nephros (NASDAQ:NEPH) in a report published on Friday morning, Marketbeat reports. The brokerage issued a market perform rating and a $4.00 price objective on the stock.

Separately, Weiss Ratings raised shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.00.

Nephros Stock Performance

Shares of Nephros stock opened at $3.78 on Friday. Nephros has a 52-week low of $2.66 and a 52-week high of $6.42. The company’s 50 day moving average price is $3.45 and its 200-day moving average price is $3.65. The stock has a market capitalization of $41.05 million, a price-to-earnings ratio of 54.01 and a beta of 1.49.

Nephros (NASDAQ:NEPH) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. The business had revenue of $5.21 million during the quarter, compared to analysts’ expectations of $5.02 million. Nephros had a net margin of 4.06% and a return on equity of 7.66%.

Institutional Trading of Nephros

Several institutional investors have recently bought and sold shares of NEPH. Kestra Advisory Services LLC bought a new position in Nephros during the fourth quarter valued at approximately $29,000. Dimensional Fund Advisors LP lifted its holdings in Nephros by 52.5% during the first quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after purchasing an additional 7,144 shares in the last quarter. Heron Bay Capital Management purchased a new position in shares of Nephros during the 4th quarter valued at $66,000. Citadel Advisors LLC lifted its position in shares of Nephros by 39.2% in the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after acquiring an additional 4,655 shares in the last quarter. Finally, XTX Topco Ltd boosted its stake in Nephros by 48.5% in the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after purchasing an additional 7,062 shares during the period. 41.10% of the stock is owned by hedge funds and other institutional investors.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.